Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Weight-Bearing CT May Improve Diagnoses in Hallux Valgus Patients

A recent analysis of studies titled Imaging of Hallux Valgus by James Welck and Naji Al-Khudairi has shown that newer, three-dimensional imaging techniques including weight-bearing computer tomography (WBCT) may permit a more thorough understanding of the hallux valgus (HV) deformity and provide greater information to foot and ankle surgeons prior to corrective surgery. Traditional two-dimensional AP, lateral, and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

A recent analysis of studies titled Imaging of Hallux Valgus by James Welck and Naji Al-Khudairi has shown that newer, three-dimensional imaging techniques including weight-bearing computer tomography (WBCT) may permit a more thorough understanding of the hallux valgus (HV) deformity and provide greater information to foot and ankle surgeons prior to corrective surgery.

Traditional two-dimensional AP, lateral, and oblique radiographs are the current standard for imaging HV deformity. Two-dimensional radiographic images can be used to measure several radiographic angles which are commonly used to quantify the extent of HV deformity. However, recent research shows that some of these angle measures show low levels of reliability and accuracy.

Coughlin et. al. found that measures of the hallux valgus angle and the intermetatarsal angle assessed using 2-D imaging had high intraobserver and interobserver reliability.

In contrast, the distal metatarsal articular angle was measured to 5° or less in only 58. 9% of cases, and measurement of metatarsophalangeal joint congruency led to a wide variation in cases identified. The primary reason that two-dimensional imaging techniques may fail to be reliable is that HV is a triplanar deformity with rotational aspects that two-dimensional images cannot account for.

Fortunately, research shows three-dimensional HV imaging techniques have promise. Conventional CT imaging is not weight-bearing, but weight-bearing cone beam CT provides better insight into HV. This means that many patients imaged through traditional CT may not have been diagnosed correctly.

  • Welck and colleagues have found WBCT to better display the sesamoids, which are difficult to represent accurately using traditional AP radiographs.
  • Collan and colleagues demonstrated the importance that CT is weight-bearing by finding that there were significant differences in HVAs and IMAs between HV and control groups only when patients were in a weight-bearing stance.

Two other research groups found that WBCT provided insight into the effects of joint hypermobility in HV patients which would not typically be measurable using two-dimensional imaging techniques.

To learn more about how three-dimensional imaging techniques like WBCT can benefit your foot and ankle practice, visit http://www.curvebeam.com/products/pedcat/. CurveBeam’s PedCAT systems are at the cutting edge of WBCT innovation and can help provide your patients with the best HV care that current science has to offer.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512